세계의 흡입제 수탁 제조 시장 - 규모, 점유율, 동향 분석 보고서 : 서비스별, 제품별, 최종 용도별, 지역별 부문 예측(2025-2033년)

Inhaled Drugs Contract Manufacturing Market Summary

The global inhaled drugs contract manufacturing market size was estimated at USD 5.47 billion in 2024 and is projected to reach USD 12.56 billion by 2033, growing at a CAGR of 9.82% from 2025 to 2033. The market growth is driven due to the rising prevalence of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD), which is fueling the demand for effective and targeted therapeutic options.

The growing clinical need, coupled with the expanding adoption of advanced inhalation therapies, is prompting pharmaceutical and biopharmaceutical companies to increasingly outsource drug development and manufacturing processes to specialized contract manufacturing, which is contributing to the growth of the inhaled drugs contract manufacturing industry.

In addition, the rising patient population suffering from chronic respiratory conditions, including asthma, COPD, among others, has accelerated the demand for effective inhalation therapies, including dry powder inhalers (DPIs), metered-dose inhalers (MDIs), and nebulizers. This growing therapeutic need is pushing pharmaceutical companies to expand their product pipelines and bring novel inhaled formulations to market faster. Developing these therapies requires specialized expertise in formulation, particle size optimization, and device compatibility, along with precision in dose delivery. Therefore, pharmaceutical companies are increasingly partnering with contract manufacturers organizations (CMOs) to leverage their technical capabilities, advanced infrastructure, and regulatory experience to enable faster development timelines and reduced capital expenditure. Thus, the aforementioned factors are driving the expansion of the inhaled drugs contract manufacturing market.

Furthermore, the need for cost optimization and operational efficiency is further accelerating the demand for contract manufacturing services in this market. Inhaled drug manufacturing involves high capital investment in device integration, cleanroom facilities, and aerosol testing, which can strain in-house resources. CDMOs with end-to-end capabilities, including formulation development, device engineering, and commercial-scale manufacturing, enable drug developers to minimize capital expenditure and accelerate time-to-market. This strategic outsourcing allows pharmaceutical companies to focus on core competencies such as research and marketing. At the same time, contract manufacturers benefit from long-term partnerships and recurring production contracts, contributing to sustained market growth.

Global Inhaled Drugs Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global inhaled drugs contract manufacturing market report based on service, product, end-use, and region:

• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical Manufacturing
• Commercial Manufacturing
• Packaging & Labeling
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Active Pharmaceutical Ingredient (API)
• Finished Drug Service
• Metered- dose inhalers (MDIs)
• Dry Powder Inhalers
• Nebulizers
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical Companies
• Biopharmaceutical Companies
• Medical Device Companies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Norway
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Value chain based analysis (Model 2)
  • 1.7.3. Multivariate Analysis (Model 3)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Landscape Insights

Chapter 3. Inhaled Drugs Contract Manufacturing Market: Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Inhaled Drugs Contract Manufacturing Market Dynamics
  • 3.2.1. Market Driver Impact Analysis
  • 3.2.2. Market Restraint Analysis
  • 3.2.3. Market Opportunities
• 3.3. Technological Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Supply Chain Analysis
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Forces Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Inhaled Drugs Contract Manufacturing Market: Service Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Inhaled Drugs Contract Manufacturing Market Service Movement Analysis
• 4.3. Global Inhaled Drugs Contract Manufacturing Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
• 4.4. Clinical Manufacturing
  • 4.4.1. Clinical Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD million)
• 4.5. Commercial Manufacturing
  • 4.5.1. Commercial Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Packaging & Labeling
  • 4.6.1. Packaging & Labeling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Inhaled Drugs Contract Manufacturing Market: Product Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Inhaled Drugs Contract Manufacturing Market Product Movement Analysis
• 5.3. Global Inhaled Drugs Contract Manufacturing Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 5.4. Active Pharmaceutical Ingredient (API)
  • 5.4.1. Active Pharmaceutical Ingredient (API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Finished Drug Service
  • 5.5.1. Finished Drug Service Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Metered- dose inhalers (MDIs)
    • 5.5.2.1. Metered- dose inhalers (MDIs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Dry Powder Inhalers
    • 5.5.3.1. Dry Powder Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.4. Nebulizers
    • 5.5.4.1. Nebulizers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.5. Others
    • 5.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Inhaled Drugs Contract Manufacturing Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Inhaled Drugs Contract Manufacturing Market End Use Movement Analysis
• 6.3. Global Inhaled Drugs Contract Manufacturing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Pharmaceutical Companies
  • 6.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Biopharmaceutical Companies
  • 6.5.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Medical Device Companies
  • 6.6.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Inhaled Drugs Contract Manufacturing Market: Regional Estimates & Trend Analysis by Service, Service, End Use

• 7.1. Regional Market Dashboard
• 7.2. Global Regional Market Snapshot
• 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.6. Oman
    • 7.8.6.1. Key Country Dynamics
    • 7.8.6.2. Competitive Scenario
    • 7.8.6.3. Regulatory Framework
    • 7.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.7. Qatar
    • 7.8.7.1. Key Country Dynamics
    • 7.8.7.2. Competitive Scenario
    • 7.8.7.3. Regulatory Framework
    • 7.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
  • 8.1.1. Market Leaders
  • 8.1.2. Emerging Players
• 8.2. Inhaled Drugs Contract Manufacturing Market Share Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. Lonza Group
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service/Product Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Catalent Inc.
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service/Product Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Recipharm AB
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service/Product Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Hovione
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service/Product Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Kindeva Drug Delivery
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service/Product Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. AptarGroup Inc.
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service/Product Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Vectura Group Ltd.
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service/Product Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Siegfried Holding AG
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service/Product Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. CordenPharma
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service/Product Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. PCI Pharma Services
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service/Product Benchmarking
    • 8.3.10.4. Strategic Initiatives